We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+7.64%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$6.56B
AUM Growth
+$19.4M
Cap. Flow
-$249M
Cap. Flow %
-3.79%
Top 10 Hldgs %
37.22%
Holding
183
New
22
Increased
65
Reduced
79
Closed
14

Top Buys

Rank Stock Value
1
DXCM icon
DexCom
DXCM
+$38.5M
2
SAGE
Sage Therapeutics
SAGE
+$22M
3
SIBN icon
SI-BONE Inc
SIBN
+$19.1M
4
STE icon
Steris
STE
+$16.6M
5
CLDX icon
Celldex Therapeutics
CLDX
+$15.6M

Top Sells

Rank Stock Value
1
AXNX
Axonics, Inc. Common Stock
AXNX
+$114M
2
ISRG icon
Intuitive Surgical
ISRG
+$56.6M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$51.2M
4
VRTX icon
Vertex Pharmaceuticals
VRTX
+$28.6M
5
EVH icon
Evolent Health
EVH
+$28.5M

Sector Composition

Rank Sector Weight
1 Healthcare 99.12%
2 Industrials 0.77%
3 Technology 0.02%
4 Communication Services 0.02%
5 Consumer Staples 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ONC
101
BeOne Medicines Ltd
ONC
$32.4B
$3.9M 0.06%
24,929
-3,671
-13% -$591K
DOCS icon
102
Doximity
DOCS
$3.87B
$3.88M 0.06%
144,065
-119,970
-45% -$3.42M
SPY icon
103
State Street SPDR S&P 500 ETF Trust
SPY
$782B
$3.48M 0.05%
6,660
+4,060
+156% +$2.02M
RDY icon
104
Dr. Reddy's Laboratories
RDY
$10.5B
$3M 0.05%
204,480
-100,020
-33% -$1.46M
GILD icon
105
Gilead Sciences
GILD
$167B
$2.44M 0.04%
33,305
-18,000
-35% -$1.38M
MTEM
106
DELISTED
Molecular Templates, Inc.
MTEM
$2.31M 0.04%
1,029,820
– –
IQV icon
107
IQVIA
IQV
$34.4B
$2.11M 0.03%
8,336
+76
+0.9% +$17.7K
TEVA icon
108
Teva Pharmaceuticals
TEVA
$37.3B
$2.01M 0.03%
+142,213
New +$1.79M
NVRO
109
DELISTED
NEVRO CORP.
NVRO
$1.95M 0.03%
135,235
-62,089
-31% -$1.03M
CVS icon
110
CVS Health
CVS
$137B
$1.76M 0.03%
22,066
-9,437
-30% -$721K
CERT icon
111
Certara
CERT
$1.08B
$1.72M 0.03%
95,924
+4,709
+5% +$81.2K
AZN icon
112
AstraZeneca
AZN
$262B
$1.57M 0.02%
11,600
-14,200
-55% -$1.88M
BIIB icon
113
Biogen
BIIB
$30.4B
$1.3M 0.02%
6,008
-2,477
-29% -$580K
BMY icon
114
Bristol-Myers Squibb
BMY
$124B
$1.27M 0.02%
+23,436
New +$1.19M
ZTS icon
115
Zoetis
ZTS
$32.1B
$1.27M 0.02%
7,510
+1,720
+30% +$322K
OM icon
116
Outset Medical
OM
$77.9M
$1.27M 0.02%
38,157
-79,185
-67% -$4.01M
EHC icon
117
Encompass Health
EHC
$11.1B
$1.24M 0.02%
14,980
+3,080
+26% +$226K
CYTK icon
118
Cytokinetics
CYTK
$10.9B
$1.1M 0.02%
15,640
-3,260
-17% -$252K
GDX icon
119
VanEck Gold Miners ETF
GDX
$21.8B
$1.04M 0.02%
33,000
– –
JNJ icon
120
Johnson & Johnson
JNJ
$609B
$1.02M 0.02%
6,420
-21,860
-77% -$3.48M
PFE icon
121
Pfizer
PFE
$143B
$939K 0.01%
33,834
+10,966
+48% +$304K
GOOG icon
122
Alphabet (Google) Class C
GOOG
$4.22T
$914K 0.01%
6,000
– –
PCVX icon
123
Vaxcyte
PCVX
$8.12B
$905K 0.01%
13,244
-2,556
-16% -$177K
KRYS icon
124
Krystal Biotech
KRYS
$10.5B
$856K 0.01%
4,810
-3,190
-40% -$443K
ALKS icon
125
Alkermes
ALKS
$8.79B
$654K 0.01%
24,144
-27,968
-54% -$794K
3 4
5
6 7

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q1 2024 Portfolio in Review

As of Q1 2024, Bellevue Group held 183 positions worth $6.56B, up 0.3% from $6.54B the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Bellevue Group withdrew a net $249M in Q1 2024, closing 14 positions and reducing 79 holdings. Its most notable exit was Axonics, Inc. Common Stock, an estimated $114M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Industrials and Technology.

Against the trend, Bellevue Group opened a new position in Steris worth $16.5M.

  • Bellevue Group's largest Q1 2024 buy was Steris: 73,434 shares worth $16.5M.
  • Bellevue Group added most to DexCom in Q1 2024, an estimated $38.5M increase.
  • Bellevue Group's biggest Q1 2024 reduction was Intuitive Surgical, cutting an estimated $56.6M.
  • Bellevue Group fully exited Axonics, Inc. Common Stock in Q1 2024, selling an estimated $114M.
  • Bellevue Group's ten largest holdings make up 37% of its $6.56B portfolio in Q1 2024.
  • Bellevue Group opened 22 new positions and closed 14 in Q1 2024.
  • Bellevue Group's portfolio value rose 0.3% quarter-over-quarter to $6.56B.

Based on Bellevue Group's 13F filing for Q1 2024, filed 15 May 2024.